Inclacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | selectin P |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1256258-86-2 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6452H9930N1730O2024S42 |
| Molar mass | 145.5 kDa |
Inclacumab (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.[1][2]
This drug was developed by Genentech/Roche.
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab, American Medical Association.
This article is issued from Wikipedia - version of the 7/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.